A recent industry-wide, independent market research study reveals that 64% of supply chain executives plan to increase their expenditure in clinical trial logistics in the next two years. The nature and complexity of new drugs and their protocols entering clinical development will increase their use of dedicated supply chain providers in the space. Temperature control capabilities (57%) and guaranteed on-time delivery within specifications (53%) as well as real-time traceability of shipments (49%) were the dominant reasons for companies moving to specialty providers such as Marken, which in April announced the completion of the study. The study shows that more than 50% reported that their organization had moved their clinical trials logistics business to a dedicated supply chain provider within the previous 24 months.
The survey included 250 key decision makers of clinical trial logistics services from pharmaceutical companies, central laboratories, clinical research organizations, and manufacturing service providers in North America, Central & South America, Europe, and Asia. Key topics profiled in the survey included market trends, industry pain points, and selection criteria for logistics providers.
